Novocure Stock Price, News & Analysis

Novocure (NASDAQ: NVCR) has scheduled its third quarter 2025 financial results announcement for October 30, 2025, before U.S. markets open. The company will host a conference call and webcast at 8:00 a.m. EDT on the same day to discuss financial results for both the three and nine-month periods ending September 30, 2025.

Investors can access presentation slides and the corporate presentation through Novocure's investor relations website, which will remain available for at least 14 days after the call. The company uses its investor relations website to disclose material non-public information in compliance with Regulation FD.

Novocure (NASDAQ: NVCR) announced positive final results from its pivotal Phase 3 METIS trial evaluating Tumor Treating Fields (TTFields) therapy for brain metastases from non-small cell lung cancer (NSCLC). The trial met its primary endpoint, demonstrating a statistically significant delay in time to intracranial progression.

Key findings include a 28% lower risk of intracranial progression in patients receiving TTFields therapy with best supportive care (BSC) versus BSC alone. The median time to intracranial progression was 15.0 months for TTFields therapy compared to 7.5 months for BSC alone. The therapy showed enhanced benefits in patients receiving immune checkpoint inhibitors, with no negative impact on quality of life or neurocognition.

Novocure (NASDAQ: NVCR) has received approval from Japan's Ministry of Health, Labour and Welfare for Optune Lua® to treat unresectable advanced/recurrent non-small cell lung cancer (NSCLC). The approval is for concurrent use with PD-1/PD-L1 inhibitors in adult patients who have progressed after platinum-based chemotherapy.

The approval is backed by the Phase 3 LUNAR trial results, which demonstrated a significant 3.3-month improvement in median overall survival (13.2 months vs. 9.9 months) in the experimental arm. Notably, patients receiving Optune Lua with PD-1/PD-L1 inhibitors showed an impressive 8.0-month survival benefit (19.0 months vs. 10.8 months, P=0.02).

The device showed a favorable safety profile, with primarily low-grade skin-related events and no Grade 4 or 5 toxicities reported.

Novocure (NASDAQ: NVCR) has announced its participation in three major investor conferences in September 2025. CEO Ashley Cordova will lead fireside chats at the Wells Fargo Healthcare Conference (Sept. 4), H.C. Wainwright Global Investment Conference (Sept. 9), and Morgan Stanley Global Healthcare Conference (Sept. 10).

CFO Christoph Brackmann will join for investor meetings at the H.C. Wainwright and Morgan Stanley events. All presentations will be available via webcast on Novocure's investor relations website for at least 14 days after each event.

Novocure (NASDAQ: NVCR) has achieved a significant milestone as Spain's Ministry of Health approves coverage of Tumor Treating Fields (TTFields) therapy through the Spanish National Health System (SNS) for adult patients with newly diagnosed glioblastoma.

TTFields therapy, which uses electric fields to disrupt cancer cell division through a wearable medical device, has received CE Mark approval for treating WHO Grade 4 Glioma. The treatment is now commercially available in multiple countries across North America, Europe, and Asia, with reimbursement established in eight countries including Austria, France, Germany, Israel, Japan, Sweden, Switzerland, and the United States. To date, over 35,000 patients globally have received TTFields treatment.

Novocure (NASDAQ: NVCR) has submitted a premarket approval (PMA) application to the FDA for its Tumor Treating Fields (TTFields) therapy to treat locally advanced pancreatic cancer. The application is backed by the successful PANOVA-3 trial, which demonstrated statistically significant improvement in median overall survival for patients treated with TTFields combined with standard chemotherapy.

The trial data was featured at the 2025 ASCO Annual Meeting in the "Best of ASCO" program and published in the Journal of Clinical Oncology. The PMA was submitted as a Panel-Track Supplement to Optune Lua® and is expected to be converted to a separate original PMA, with an approval decision anticipated in second half of 2026.

Novocure (NASDAQ: NVCR) reported Q2 2025 financial results with total net revenues of $158.8 million, up 6% year-over-year. The company maintained 4,331 active patients on Tumor Treating Fields (TTFields) therapy globally.

Key financial metrics include a 74% gross margin and a net loss of $40.1 million ($0.36 per share). The company maintains a strong cash position of $911.5 million.

Significant clinical progress includes the presentation of successful Phase 3 PANOVA-3 trial results at ASCO 2025, showing statistically significant extension in overall survival for pancreatic cancer patients. The company plans FDA submissions for pancreatic cancer treatment in Q3 2025 and brain metastases from NSCLC in H2 2025.

Novocure (NASDAQ: NVCR) will present final secondary endpoint data from its Phase 3 PANOVA-3 trial at the ESMO Gastrointestinal Cancers Congress 2025. The trial evaluated Tumor Treating Fields (TTFields) therapy combined with gemcitabine and nab-paclitaxel (GnP) for treating unresectable, locally advanced pancreatic cancer.

The study demonstrated significant improvements in multiple quality of life metrics: Global health status deterioration was delayed to 7.1 months vs. 5.7 months (p=0.023), pain deterioration was extended to 10.1 months vs. 7.4 months (p=0.003), and pancreatic pain deterioration was prolonged to 14.7 months vs. 10.2 months (p=0.006) compared to GnP alone.

Additionally, the trial showed significant delay in first opioid use (7.1 months vs. 5.4 months, p=0.046) and improved pain-free survival (15.2 months vs. 9.1 months, p=0.027). TTFields therapy was well-tolerated with mild to moderate skin adverse events being the most common device-related side effects. The company plans to submit a premarket application to the FDA in the second half of 2025.

Novocure (NASDAQ: NVCR) has scheduled its second quarter 2025 financial results announcement for July 24, 2025, before U.S. markets open. The company will host a conference call and webcast at 8:00 a.m. EDT on the same day to discuss its financial performance for the three and six-month periods ending June 30, 2025.

The presentation materials will be accessible through Novocure's investor relations website and will remain available for at least 14 days after the call. The company uses its investor relations website to disclose material non-public information in compliance with Regulation FD.